{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:59:36Z","timestamp":1787752776176,"version":"build-2784847793"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T00:00:00Z","timestamp":1650758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T00:00:00Z","timestamp":1650758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To this day, there is no cure for recurrent respiratory papillomatosis (RRP). Multiple surgical procedures are performed to achieve symptom relief and prevention of airway obstruction. A promising drug for RRP is the vascular endothelial growth factor (VEGF) binding antibody bevacizumab. This chemotherapeutic agent has an angiogenesis-inhibiting effect which inhibits tumor growth. The objective of this review was to investigate the efficacy of bevacizumab as treatment option for RRP, and to explore the difference of its effects between intralesional and systemic treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic search was conducted in Cochrane, PubMed, and Embase. Articles were included if bevacizumab treatment was given intralesionally and\/or systemically. The methodological quality of the studies was assessed using the CAse REport (CARE) guidelines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 585 unique articles screened by title and abstract, 15 studies were included, yielding a total of 64 patients. In 95% of the patients treated with systemic bevacizumab, the post-bevacizumab surgical interval was considerably prolonged. More than half of them did not need any surgical intervention during mean follow-up of 21.6\u00a0months. Treatment with intralesional bevacizumab showed a lower efficacy: in 62% of the patients, the post-bevacizumab surgical interval (mean, 1.8\u00a0months follow-up) was extended when compared to the interval before the treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Systemically and intralesionally administered bevacizumab are effective treatment options for severe RRP. A systemic administration might be the treatment of first choice. Further prospective research with long term follow-up is advocated to elucidate this important topic.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00405-022-07388-6","type":"journal-article","created":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T16:03:28Z","timestamp":1650816208000},"page":"4229-4240","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Bevacizumab as treatment option for recurrent respiratory papillomatosis: a systematic review"],"prefix":"10.1007","volume":"279","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6735-508X","authenticated-orcid":false,"given":"Louis","family":"Pogoda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuat","family":"Ziylan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederik P. J.","family":"Smeeing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5265-3722","authenticated-orcid":false,"given":"Frederik G.","family":"Dikkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0056-7827","authenticated-orcid":false,"given":"Rico N. P. M.","family":"Rinkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,24]]},"reference":[{"issue":"4","key":"7388_CR1","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.otc.2019.03.011","volume":"52","author":"CS Derkay","year":"2019","unstructured":"Derkay CS, Bluher AE (2019) Update on recurrent respiratory papillomatosis. Otolaryngol Clin N Am 52(4):669\u2013679","journal-title":"Otolaryngol Clin N Am"},{"issue":"12","key":"7388_CR2","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1097\/INF.0000000000000551","volume":"33","author":"LJ Wilcox","year":"2014","unstructured":"Wilcox LJ, Hull BP, Baldassari CM, Derkay CS (2014) Diagnosis and management of recurrent respiratory papillomatosis. Pediatr Infect Dis J 33(12):1283\u20131284","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"7388_CR3","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/coa.12565","volume":"41","author":"MR San-Giorgi","year":"2016","unstructured":"San-Giorgi MR, van den Heuvel ER, Tjon-Pian-Gi RE et al (2016) Age of onset of recurrent respiratory papillomatosis: a distribution analysis. Clin Otolaryngol 41(5):448\u2013453","journal-title":"Clin Otolaryngol"},{"issue":"6","key":"7388_CR4","doi-asserted-by":"publisher","first-page":"e0216697","DOI":"10.1371\/journal.pone.0216697","volume":"14","author":"FJ Buchinsky","year":"2019","unstructured":"Buchinsky FJ, Valentino WL, Ruszkay N et al (2019) Age at diagnosis, but not HPV type, is strongly associated with clinical course in recurrent respiratory papillomatosis. PLoS ONE 14(6):e0216697","journal-title":"PLoS ONE"},{"issue":"1","key":"7388_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/lio2.132","volume":"3","author":"R Ivancic","year":"2018","unstructured":"Ivancic R, Iqbal H, deSilva B, Pan Q, Matrka L (2018) Current and future management of recurrent respiratory papillomatosis. Laryngosc Investig Otolaryngol 3(1):22\u201334","journal-title":"Laryngosc Investig Otolaryngol"},{"issue":"8","key":"7388_CR6","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1002\/lary.26413","volume":"127","author":"MRM San Giorgi","year":"2017","unstructured":"San Giorgi MRM, Aaltonen LM, Rihkanen H et al (2017) Quality of life of patients with recurrent respiratory papillomatosis. Laryngoscope 127(8):1826\u20131831","journal-title":"Laryngoscope"},{"issue":"7","key":"7388_CR7","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ijporl.2008.04.003","volume":"72","author":"AJ Donne","year":"2008","unstructured":"Donne AJ, Rothera MP, Homer JJ (2008) Scientific and clinical aspects of the use of cidofovir in recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 72(7):939\u2013944","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"9","key":"7388_CR8","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1001\/archotol.130.9.1039","volume":"130","author":"S Schraff","year":"2004","unstructured":"Schraff S, Derkay CS, Burke B, Lawson L (2004) American Society of Pediatric Otolaryngology members\u2019 experience with recurrent respiratory papillomatosis and the use of adjuvant therapy. Arch Otolaryngol Head Neck Surg 130(9):1039","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"7388_CR9","doi-asserted-by":"publisher","first-page":"110352","DOI":"10.1016\/j.ijporl.2020.110352","volume":"138","author":"YI Baday","year":"2020","unstructured":"Baday YI, Ongkasuwan J, Venkatramani R (2020) Systemic bevacizumab for recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 138:110352","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"7388_CR10","doi-asserted-by":"publisher","first-page":"842","DOI":"10.12659\/AJCR.904416","volume":"18","author":"A Bedoya","year":"2017","unstructured":"Bedoya A, Glisinski K, Clarke J, Lind RN, Buckley CE, Shofer S (2017) Systemic bevacizumab for recurrent respiratory papillomatosis: a single center experience of two cases. Am J Case Rep 18:842\u2013846","journal-title":"Am J Case Rep"},{"issue":"10","key":"7388_CR11","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1002\/lary.26662","volume":"127","author":"SR Best","year":"2017","unstructured":"Best SR, Mohr M, Zur KB (2017) Systemic bevacizumab for recurrent respiratory papillomatosis: a national survey. Laryngoscope 127(10):2225\u20132229","journal-title":"Laryngoscope"},{"issue":"4","key":"7388_CR12","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/lary.27674","volume":"129","author":"C Carnevale","year":"2019","unstructured":"Carnevale C, Ferr\u00e1n-De-la-Cierva L, Til-P\u00e9rez G et al (2019) Safe use of systemic bevacizumab for respiratory recurrent papillomatosis in two children. Laryngoscope 129(4):1001\u20131004","journal-title":"Laryngoscope"},{"key":"7388_CR13","doi-asserted-by":"publisher","first-page":"109762","DOI":"10.1016\/j.ijporl.2019.109762","volume":"129","author":"C Gates","year":"2020","unstructured":"Gates C, Tomboc P, Allison A, Carr M (2020) Bevacizumab as adjuvant therapy for recurrent respiratory papillomatosis in an infant. Int J Pediatr Otorhinolaryngol 129:109762","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"7388_CR14","doi-asserted-by":"publisher","first-page":"109706","DOI":"10.1016\/j.ijporl.2019.109706","volume":"128","author":"O Hamdi","year":"2020","unstructured":"Hamdi O, Dome J, Zalzal G, Preciado D (2020) Systemic bevacizumab for end-stage juvenile recurrent respiratory papillomas: a case report. Int J Pediatr Otorhinolaryngol 128:109706","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"6","key":"7388_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archoto.2010.81","volume":"136","author":"S Maturo","year":"2010","unstructured":"Maturo S, Hartnick CJ (2010) Use of 532-nm pulsed potassium titanyl phosphate laser and adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children: Initial experience. Arch Otolaryngol Head Neck Surg 136(6):561\u2013565","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"5","key":"7388_CR16","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.3892\/ol.2014.2486","volume":"8","author":"M Mohr","year":"2014","unstructured":"Mohr M, Schliemann C, Biermann C et al (2014) Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis. Oncol Lett 8(5):1912\u20131918","journal-title":"Oncol Lett"},{"issue":"7","key":"7388_CR17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1055\/s-0029-1214714","volume":"63","author":"S Nagel","year":"2009","unstructured":"Nagel S, Busch C, Blankenburg T, Sch\u00fctte W (2009) Behandlung der respiratorischen papillomatose kasuistik zur systemischen therapie mit bevacizumab1. Pneumologie 63(7):387\u2013389","journal-title":"Pneumologie"},{"issue":"5","key":"7388_CR18","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1001\/jamaoto.2013.1810","volume":"139","author":"DJ Rogers","year":"2013","unstructured":"Rogers DJ, Ojha S, Maurer R, Hartnick CJ (2013) Use of adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children. JAMA Otolaryngol Head Neck Surg 139(5):496\u2013501","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"3","key":"7388_CR19","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1177\/0003489414522977","volume":"123","author":"DR Sidell","year":"2014","unstructured":"Sidell DR, Nassar M, Cotton RT, Zeitels SM, De Alarcon A (2014) High-dose sublesional bevacizumab (avastin) for pediatric recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 123(3):214\u2013221","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"7388_CR20","first-page":"1","volume":"131","author":"A Tkaczuk","year":"2020","unstructured":"Tkaczuk A, Trivedi S, Mody MD et al (2020) Parenteral bevacizumab for the treatment of severe respiratory papillomatosis in an adult population. Laryngoscope 131:1\u20138","journal-title":"Laryngoscope"},{"issue":"7","key":"7388_CR21","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1002\/lary.26450","volume":"127","author":"KB Zur","year":"2017","unstructured":"Zur KB, Fox E (2017) Bevacizumab chemotherapy for management of pulmonary and laryngotracheal papillomatosis in a child. Laryngoscope 127(7):1538\u20131542","journal-title":"Laryngoscope"},{"issue":"1","key":"7388_CR22","first-page":"E72","volume":"117","author":"G Cuestas","year":"2019","unstructured":"Cuestas G, Rodr\u00edguez V, Doormann F, Munz\u00f3n PB, Munz\u00f3n GB (2019) Tracheobronchial and pulmonary papillomatosis without involvement of the larynx treated with intravenous Bevacizumab in a child. Archivos Argentinos de Pediatria 117(1):E72\u2013E76","journal-title":"Archivos Argentinos de Pediatria"},{"issue":"5","key":"7388_CR23","first-page":"103126","volume":"42","author":"OH Enrique","year":"2021","unstructured":"Enrique OH, Eloy SH, Adrian TP, Perla V (2021) Systemic bevacizumab as adjuvant therapy for recurrent respiratory papillomatosis in children: a series of three pediatric cases and literature review. Am J Otolaryngol Head Neck Med Surg 42(5):103126","journal-title":"Am J Otolaryngol Head Neck Med Surg"},{"key":"7388_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/lary.29343","volume":"131","author":"DR Sidell","year":"2021","unstructured":"Sidell DR, Balakrishnan K, Best SR et al (2021) Systemic bevacizumab for treatment of respiratory papillomatosis: international consensus statement. Laryngoscope 131:1\u20139","journal-title":"Laryngoscope"},{"key":"7388_CR25","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535","journal-title":"BMJ"},{"key":"7388_CR26","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700","journal-title":"BMJ"},{"issue":"1","key":"7388_CR27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jclinepi.2013.08.003","volume":"67","author":"JJ Gagnier","year":"2014","unstructured":"Gagnier JJ, Kienle G, Altman DG et al (2014) The CARE guidelines: consensus-based clinical case report guideline development. J Clin Epidemiol 67(1):46\u201351","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"7388_CR28","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/hed.23808","volume":"37","author":"RE Tjon-Pian-Gi","year":"2015","unstructured":"Tjon-Pian-Gi RE, San Giorgi MR, Slagter-Menkema L et al (2015) Clinical course of recurrent respiratory papillomatosis: comparison between aggressiveness of human papillomavirus-6 and human papillomavirus-11. Head Neck 37(11):1625\u20131632","journal-title":"Head Neck"},{"key":"7388_CR29","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"J Garcia","year":"2020","unstructured":"Garcia J, Hurwitz HI, Sandler AB, Miles D et al (2020) Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev 86:102017","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"7388_CR30","doi-asserted-by":"publisher","first-page":"e2254","DOI":"10.1002\/onco.13971","volume":"26","author":"AM Oza","year":"2021","unstructured":"Oza AM, Dubois F, Hegg R et al (2021) A long-term extension study of bevacizumab in patients with solid tumors. Oncologist 26(12):e2254\u2013e2264","journal-title":"Oncologist"},{"issue":"1","key":"7388_CR31","first-page":"26","volume":"28","author":"L Pogoda","year":"2022","unstructured":"Pogoda L, Ziylan F, Dikkers F, Rinkel R (2022) Bevacizumab as treatment option for recurrent respiratory papillomatosis: a case report. Nederlands Tijdschrift voor Keel-Neus-Oorheelkunde 28(1):26\u201330 (in Dutch)","journal-title":"Nederlands Tijdschrift voor Keel-Neus-Oorheelkunde"},{"issue":"5","key":"7388_CR32","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/lary.29084","volume":"131","author":"MA Ryan","year":"2021","unstructured":"Ryan MA, Leu GR, Upchurch PA, Tunkel DE, Walsh JM, Boss EF (2021) Systemic bevacizumab (Avastin) for juvenile-onset recurrent respiratory papillomatosis: a systematic review. Laryngoscope 131(5):1138\u20131146","journal-title":"Laryngoscope"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-022-07388-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-022-07388-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-022-07388-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T04:07:29Z","timestamp":1660018049000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-022-07388-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,24]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["7388"],"URL":"https:\/\/doi.org\/10.1007\/s00405-022-07388-6","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,24]]},"assertion":[{"value":"5 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}